1. World Health Organization. WHO definition of palliative care. Available at: www.who.int/cancer/palliative/definition/en. Accessed April 1, 2006.
2. Trauma care and palliative care: time to integrate the two?
J Am Coll Surg. 2003; 197:509–516., .
3. Improving palliative care for patients in the intensive care unit. J Palliat Med. 2005; 8:840–854., .
4. Secondary and tertiary palliative care in US hospitals. JAMA. 2002; 287:875–888..
5. Pediatric palliative care. NEJM. 2004; 350:1752–1762., , , .
6. www.capc.org/capc-growth-analysis-snapshot-2011.pdf. Accessed 18 Sept 2014.
7. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363(8):733–742
, , , et al.
8. Do palliative consultations improve patient outcomes?
J Am Geriatr Soc. 2008; 56(4):593–599., , , et al.
9. Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients. Critical Care Medicine. 2007; 35:1530–1535
, , , et al.
10. Financial impact of palliative care consultation in a public hospital. J Palliat Med
2008; 11(10):1304–1408., , , .
11. Palliative Care Leadership Centers' Outcomes Group. Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med. 2008; 168(16):1783–1790., , , et al.
12. Can palliative home care reduce 30-day readmissions? results of a propensity score matched cohort study. J Palliat Med. 2013; 16(10):1290–1293
, , , .
13. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc.
2007; 55: 993–1000., , , et al.
14. Palliative care. NEJM. 2004; 350:2582–2590.,
15. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012; 367(17):1616–1625., , , et al.
16. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984; 2:187–193., , .
17. Survival prediction interminal cancer patients: a systematic review of the medical literature. Palliat Med. 2000; 14: 363–374., , , , .
18. Estimating length of survival in end-stage cancer: a review of the literature. J Pain Symptom Manage. 1995; 10:548–555..
19. Complexities in prognostication in advancer cancer. “To help them live their lives the way they want to.”
JAMA. 2003; 290:98–104., .
20. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer. 1995; 75:2613–2622., , , et al.
21. Clinical symptoms and length of survival in patients with terminal cancer. Arch Int Med. 1988; 148:1586–1591., , .
22. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994; 74:1965–1973., , , et al.
23. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations – a study for the steering committee of the European Association for Palliative Care. J Clin Oncol. 2005; 23:6240–6248., , , et al.
24. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med. 1990; 112:499–504., , , , .
25. Clin Oral Investig. 2001; 5:194–198., , , et al.
26. 2006. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu., . Fast facts and concepts #151; Hypercalcemia of malignancy. February
27. Whole-brian radiotherapy in the management of brain metastasis. J Clin Onc. 2006; 24:1295–1304., , , .
28. The systemic inflammation-based glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39(5):534–540..
29. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol. 2007; 25(22):3313–3320., , , et al.
30. Extent and determinants of error in physicians’ prognoses in terminally ill patients: prospective cohort study. West J Med. 2000; 172(5):310–313., .
31. A systematic review of physicians’ survival predictions in terminally ill cancer patients. BMJ. 2003; 327:195–201., , , et al.
32. Extent and determinants of error in doctors’ prognoses in terminally ill patients: prospective cohort study. BMJ. 2000; 320:469–473., .
33. Prognostic disclosure to patients with cancer near the end of life. Ann Int Med. 2001; 134:1096–1105., .
34. Communicating prognosis in cancer care: a systematic review of the literature. Ann Oncol. 2005; 16:1005–1053., , , , .
35. Receiving bad news: patients with haematological cancer reflect upon their experience. Palliat Med. 2005; 19:594–601., .
36. 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu.. Fast facts and concepts #13; Determining prognosis in advanced cancer. 2nd Edition, July
37. 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu., . Fast facts and concepts #6; Delivering bad news: part 1. 2nd Edition, July
38. 2005. End-of-Life Palliative Education Resource Center. www.eperc.mcw.edu., . Fast facts and concepts #11; Delivering bad news; part 2. 2nd Edition, September
39. Decision making at a time of crisis near the end of life. JAMA. 2004; 292:1738–1743..
40. Adjuvant analgesics in cancer pain management. The Oncol. 2004; 9:571–591., , .
41. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage. 2001; 21:144–150., .
42. Pain in terminally ill patients. Guidelines for pharmacological management. CNS Drugs. 2003; 17:621–631., .
43. Principles and Practice of Palliative Care and Supportive Oncology, 2nd edition. New York, NY: Lippincott Williams and Wilkins; 2002:3–52.. Cancer pain: principles of assessment and syndromes. In: , , , eds.
44. Nonpharmacologic and complementary approaches to cancer pain management. J Am Osteopath Assoc. 2005; 105:S15–20., .
45. Music therapy in hospice and palliative care: a review of the empirical data. eCAM. 2005; 2:173–178..
46. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. J Pain Symptom Manage. 1999; 17:351–356., , , , et al.
47. A randomized controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy: effects on dose-escalation and a pharmacoeconomic analysis. Eu J Cancer. 2002; 38:1358–1363., , .
48. Controversies in pharmacotherapy of pain management. Lancet Oncol. 2005; 6:696–704., , , .
49. The role of tramadol in cancer pain treatment – a review. Supp Care Cancer. 2005; 13:5–17
50. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001; 84:587–593
, , , et al.
51. Goodman and Gilman's: the Pharmacological Basis of Therapeutics, 10th Ed. New York, NY: McGraw-Hill; 2001:569–619., . Opioid analgesics. In: , , eds.
52. . Fast facts and concepts #71: Meperidine for pain: What's all the fuss? June 2002. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
53. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med. 2005; 6: 305–314., , , .
54. Methadone use in cancer patients with pain: a review. J Palliative Med. 2002; 5:127–138., .
55. Gordon DB, Weissman DE. Fast facts and concepts #70: PRN range analgesic orders. June 2002. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.
56. The role of opioids in cancer pain. BMJ. 2005; 331:825–829..
57. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004; 28:497–504.
58. Barriers to cancer pain relief: fear of tolerance and addiction. J Pain Symptom Manage. 1998; 16:1–9., ,
59. Long-term patterns of morphine dose and pain intensity among cancer patients. Hosp J. 1999; 14:35–47., .
60. Is disease progression the major factor in morphine ‘tolerance’ in cancer pain treatment?
Pain. 1993; 55:319–326., , , et al.
61. National Cancer Institute. Substance Abuse Issues In Cancer (PDQ). Available at: www.cancer.gov/cancertopics/pdq/supportivecare/substanceabuse/healthprofessional. Accessed April 1, 2006.
62. Addiction-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med
, , .
63. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guideline. J Pain. 2009; 10(2):131–146
, , , , , .
64. Screening for opioid misuse and abuse. Fast Facts and Concepts. August 2011; 244. www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_244.htm
65. [Anonymous]. Management of chronic pain syndromes: issues and interventions. Pain Med. 2005; 6: S1–S21.
66. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the gabapentin cancer pain study group. J Clin Oncol. 2004; 22:2909–2917., , , et al.
67. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. J Supp Oncol. 2006; 4:43–52., .
68. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013; 309(13):1359–1367., , , et al.
69. The pharmacological treatment of bone pain. Cancer Surv. 1988; 7:87–101..
70. Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. Gulf J Oncolog. 2007; 1(1):35–41., , .
71. External beam radiotherapy for painful bone metastases from hepatocellular carcinoma: multiple fractions compared with an 8-gy single fraction. Nagoya J Med Sci. 2014; 76(1–2):91–99., ,
72. Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003; 55(3):594–605., , , , ,
73. Percutaneous ablation: safe, effective treatment of bone tumors. Oncology (Williston Park). 2005; 19(11 Suppl 4):22–26., .
74. Radiofrequency ablation of bony metastatic disease. Clin Radiol. 2004; 59(9):803–811., , .
75. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005; 6:392–400., , .
76. Radiofrequency ablation of bony metastatic disease. Clin Radiol. 2004; 59:803–811., , .
77. Treating osteoporotic and neoplastic vertebral compression fractures with vertebroplasty and kyphoplasty. J Palliat Med. 2005; 8:931–938., , , et al.
78. Fundamentals of interventional pain medicine. The Neurol. 2005; 11:285–293., , .
79. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer. A randomized controlled trial. JAMA. 2004; 291:1092–1099., , .
80. Treatment of nausea and vomiting in advanced cancer. Support Care Cancer. 2000; 8:444–452., .
81. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997; 76:1055–61., , , et al.
82. 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology. 2005; 69:97–109.
83. Update on anti-emetics for chemotherapy-induced emesis. Intern Med J. 2005; 35:478–481..
84. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003; 21:4077–4080., , , et al.
85. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005; 104:1548–1555., , , et al.
86. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014; 22(4):1143–1151
87. Ondansetron is more effective than metoclopramide for the tratement of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol. 1999; 16:669–677., , , et al.
88. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supp Care Cancer. 2004; 12:432–440., , , , .
89. Chronic nausea in advancer cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage. 1996; 11:147–153., , , et al.
90. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 1998; 83:1214–1243., , , .
91. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage. 2001; 22:631–634., , , et al.
92. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002; 23:526–532., , .
93. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage. 2003; 25:485–488., , , et al.
94. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Supp Care Cancer. 2005; 13:529–534., , , et al.
95. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2014; 47(3):542–550., , , et al.
96. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29(31):4189–4198., , , et al.
97. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Supp Care Cancer. 2013; 21(6):1655–1663., , .
98. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001; 323:1–8., , , , , .
99. Established and potential therapeutic applications of cannabinoids in oncology. Supp Care Cancer. 2003; 11:137–143., , .
100. www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Accessed June 23, 2014.
101. Survey of Australians using cannabis for medical purposes. Harm Reduct J. 2005; 2:18., ,
102. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013; 24(6):511–516., , , et al.
103. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol. 2012; 83(1):1–10., , , .
104. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995; 18:170–175., , , , , .
105. Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Onc. 2005; 23:7188–7198., , , et al.
106. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manage. 2003; 26:731–742., , , et al.
107. Constipation in advanced cancer patients. Supp Care Cancer. 1998; 6:356–364.,
108. Symptom evaluation in palliative medicine: patients report vs systematic assessment. Supp Care Cancer. 2006; 14:444–453., , , et al.
109. ABC of palliative care: constipation and diarrhoea. BMJ. 1997; 315:1293–1296., .
110. Management of opioid-induced bowel dysfunction in cancer patients. Supp Care Cancer. 2004; 12:613–618., .
111. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine. 2005; 30:2484–2490., , ,
112. Oral naloxone reverses opioid-associated constipation. Pain. 2000; 84:105–109., , , , .
113. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med. 1996; 10:135–44..
114. Pharmacological treatment of constipation in palliative care. Curr Opin Support Palliat Care. 2013; 7(2):183–191., , , .
115. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; 358(22):2332–2343., , , et al.
116. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008; 35(5):458–468., , , et al.
117. Systematic review of the treatment of cancer–associated anorexia and weight loss. J Clin Oncol. 2005; 23:8500–8511., , , , .
118. The syndrome of anorexia–cachexia. Curr Opin Oncol. 1999; 11:225–260..
119. Is there evidence for earlier intervention in cancer-associated weight loss?
J Supp Oncol. 2003; 1:279–286..
120. Anorexia: a taste of things to come?
Palliat Med. 2006; 20:43–45.
121. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer. 1998; 82:553–560., , , , , .
122. Standards, options, and recommendations for the use of appetite stimulants in oncology (2000). Br J Cancer. 2003; 89:S98–S100., , , et al.
123. Cancer-related fatigue: an update. Curr Oncol Rep. 2005; 7:277–282., .
124. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiat. 2003; 54:283–294., .
125. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005; 104:1772–1778., , , , , .
126. Assessment and management of cancer-related fatigue in adults. Lancet. 2003; 362:640–650., , ,
127. Transforming the nature of fatigue through exercise: qualitative findings from a multidimensional exercise programme in cancer patients undergoing chemotherapy. Eur J Cancer Care. 2004; 13:362–370.. , , , ,
128. Assessing the clinical significance of health-related quality of life (HRQoL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer
2003; 39:335–345., , , et al.
129. Evidence-based treatment for cancer-related fatigue. J Natl Cancer Inst Monograph. 2004; 32:112–118..
130. Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival. J Supp Oncol. 2003; 1:249–258..
131. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med. 2005; 8:1144–1149., , , , .
132. Use of red blood cell transfusions in terminally ill cancer patients admitted to a palliative care unit. J Pain Symptom Manage. 1996; 12:18–22., , , .
133. Patient-controlled methylphenidate for the management of fatigue in patients with advancer cancer: a preliminary report. J Clin Oncol. 2003; 21:4439–4443., , .
134. Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc. 2001; 33:718–723., , , , .
135. Effects of physicial activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999; 85:2273–2277., , , , .
136. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol. 2004; 15:712–720., , .
137. Management of malignant pleural effusions and ascites. J Supp Oncol. 2005; 3:169–176..
138. Malignant ascites. Clinical and experimental observations. Ann Surg. 1986; 203:644–651., , , .
139. Ascitic fluid analysis in malignancy-related ascites. Hepatol. 1988; 8:1104–1109., , .
140. A survey of practice in management of malignant ascites. J Pain Symptom Manage. 1998; 16:96–101., , .
141. Advances in critical care hepatology. Am J Respir Crit Care Med. 2003; 168:1421–1426., , .
142. Prevalence of anxiety and depression in cancer patients seen at the Norwegian Radium Hospital. Eur J Cancer. 1997; 33:1597–604., , , .
143. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monograph. 2004; 32:32–39..
144. Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care. Supp Care Cancer. 2001; 9:477–488., , , ,
145. Recent developments and current controversies in depression. Lancet. 2006; 367:153–167., , .
146. Effect of depression on diagnosis, treatment, and survival of older women with breast cancer. J Am Geri Soc. 2004; 52:106–111., , .
147. Depression as a prognostic factor for breast cancer mortality. Psychosomat. 2003; 44:24–30., , , , , .
148. Oncologists’ recognition of depression in their patients with cancer. J Clin Oncol. 1998; 16:1594–1600., , , , , .
149. 43: Is it grief or depression? August 2005. 2nd edition. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu
. Fast facts and concepts #
150. “Are you depressed?” Screening for depression in the terminally ill. Am J Psychiat. 1997; 154:674–676., , , .
151. 2005. End-of-Life Physician Education Resource Center. www.eperc.mcw.edu.. Fast fact and concept #146: Screening for depression in palliative care. December
152. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol. 1991; 9:1004–1011., , , et al.
153. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer. 1999; 80:1770–1780., .
154. Treatment of major depression with psychotherapy or psychotherapy–pharmacotherapy combinations. Arch Gen Psychiatry. 1997; 54:1009–15., , , et al.
155. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363(8):733–742., , , et al.
156. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacother. 2006; 25:269–276., , .
157. Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Safety. 2005; 4:337–344., , , .
158. Vanlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiat. 2006; 67:72–80., , , , .
159. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005; 6:346–356., , , et al.
160. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002; 23:442–447., , , , .
161. Depression with psychomotor retardation: diagnostic challenges and the use of psychostimulants. J Palliat Med. 2001; 4:15–21.,
162. Depression and anxiety in women with early breast cancer: five year observational cohort study. BMJ. 2005; 330:702., , , , ,
163. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol. 2004; 9:569–581., , , .
164. The gynecologic oncology consult: symptom presentation and concurrent symptoms of depression and anxiety. Obstet Gynecol. 2004; 103:1211–1217., , , , .
165. Aromatherapy and massage for symptom relief in patients with cancer. Cochrane Database of Systematic Reviews. (2): CD002287, 2004., , .
166. Relaxation and imagery for anxiety and depression control in community patients with advanced cancer. Cancer Nurs. 2002; 25:432–435..
167. Anxiety and the adult cancer patient. Eur J Cancer Care. 1998; 7:217–224..
168. Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiat. 2004; 65:S8–S13..